France · Health Care · EUR (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in EUR (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for CARMAT? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | 108.32% | - | -263.8% | -278.85% | -279.76% | -282.72% |
|---|---|---|---|---|---|---|
| ROA | -107.63% | -18.01% | -13.19% | -13.94% | -13.99% | -14.14% |
| Gross Margin | -336.56% | 15% | 15% | 15% | 15% | 15% |
| Net Margin | -734.21% | -98.09% | -72.42% | -74.1% | -76.41% | -77.52% |
| Total Assets | €42,431.00K | €45,876.46K | €49,640.26K | €53,752.15K | €58,244.65K | €62,354.48K |
| Net Income | -€51,395.00K | -€7,950.28K | -€6,299.25K | -€7,207.80K | -€7,833.01K | -€8,524.03K |